{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:19:04Z","timestamp":1781925544013,"version":"3.54.5"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ctrv.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T13:18:12Z","timestamp":1522847892000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Bispecific antibodies in haematological malignancies"],"prefix":"10.1016","volume":"65","author":[{"given":"Andreas","family":"Viardot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Bargou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2018.04.002_b0005","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the major component of a peptic digest of rabbit antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2018.04.002_b0010","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/314628a0","article-title":"Hybrid antibodies can target sites for attack by T cells","volume":"314","author":"Staerz","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2018.04.002_b0015","first-page":"12","article-title":"Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on","volume":"12","author":"Riethmueller","year":"2012","journal-title":"Cancer immunity"},{"key":"10.1016\/j.ctrv.2018.04.002_b0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0140-6736(90)90205-J","article-title":"Preliminary trial of specific targeting therapy against malignant glioma","volume":"335","author":"Nitta","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.04.002_b0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01525390","article-title":"CD8 T cell activation after intravenous administration of CD3\u202f\u00d7\u202fCD19 bispecific antibodies in patients with non-Hodgkin lymphoma","volume":"40","author":"de Gast","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2018.04.002_b0030","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.V89.6.2042","article-title":"Treatment of refractory Hodgkin's disease with an anti-CD16\/CD30 bispecific antibody","volume":"89","author":"Hartmann","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0035","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibodiy construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2018.04.002_b0040","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19\u202f\u00d7\u202fCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2018.04.002_b0050","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"32","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2018.04.002_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed ALL","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2018.04.002_b0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ctrv.2018.04.002_b0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.ctrv.2018.04.002_b0070","unstructured":"Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: a review. Pharmacol Ther 2017; pii: S0163-7258(17)30293-0 [Epub ahead of print]. Pubmed PMID: 29269044. https\/\/doi.org\/10.1016\/j.pharmthera.2017.12.002 [Epub ahead of print]."},{"key":"10.1016\/j.ctrv.2018.04.002_b0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-017-0072-7","article-title":"The development of bispecific antibodies and their applications in tumor immune escape","volume":"6","author":"Zhang","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0085","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2018.04.002_b0090","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage ALL patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0095","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood 2018; Jan 22. pii: blood-2017-08-798322 [Epub ahead of print]. http:\/\/doi.org\/10.1182\/blood-2017-08-798322.","DOI":"10.1182\/blood-2017-08-798322"},{"key":"10.1016\/j.ctrv.2018.04.002_b0100","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows haematologic and molecular remissions in patients with relapsed or refractory B-precursor ALL","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0110","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete haematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-Positive B-precursor ALL following treatment with blinatumomab: results from a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0115","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory ALL","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0120","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced ALL","volume":"376","author":"B Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.002_b0125","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of haematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0130","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0135","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"S Assi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ctrv.2018.04.002_b0140","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0145","doi-asserted-by":"crossref","unstructured":"Dufner V, Goebeler ML, Saheli C, Bargou RC. Bispecific T-cell engager antibody construct blinatumomab shows durable response in a long-term follow-up analysis of 38 NHL Patients Treated in a Phase I Trial. Blood 126 (23, supplement): 3974.","DOI":"10.1182\/blood.V126.23.3974.3974"},{"key":"10.1016\/j.ctrv.2018.04.002_b0150","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0155","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0160","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory ALL","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0165","doi-asserted-by":"crossref","unstructured":"Jabbour E, D\u00fcll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, et al. Outcome of patients with relapsed\/refractory ALL after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol 2017 Nov 27 [Epub ahead of print]. Pubmed PMID: 29178361. http:\/\/doi.org\/10.1002\/ajh.24987.","DOI":"10.1002\/ajh.24987"},{"key":"10.1016\/j.ctrv.2018.04.002_b0170","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.ctrv.2018.04.002_b0175","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in ALL may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.25953","article-title":"Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy","volume":"63","author":"Rayes","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2018.04.002_b0185","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/leu.2016.18","article-title":"The possible perils of targeted therapy","volume":"30","author":"Duffner","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2018.04.002_b0190","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","article-title":"Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy","volume":"130","author":"Nagel","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"K\u00f6hnke","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0200","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.04.002_b0205","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2018.04.002_b0210","doi-asserted-by":"crossref","unstructured":"Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT Jr, Trippett T, et al. Blinatumomab retreatment after relapse in patients with relapsed\/refractory B-precursor ALL. Leukemia 2017 Oct 9 [Epub ahead of print]. Pubmed PMID: 28990581. http:\/\/doi.org\/10.1038\/leu.2017.306.","DOI":"10.1038\/leu.2017.306"},{"key":"10.1016\/j.ctrv.2018.04.002_b0215","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells","volume":"7","author":"Reusch","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.ctrv.2018.04.002_b0220","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-16-0666","article-title":"MGD011, A CD19\u202f\u00d7\u202fCD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.002_b0225","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/ijc.23626","article-title":"Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20\u202f\u00d7\u202fanti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels","volume":"123","author":"Stanglmaier","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2018.04.002_b0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1479-5876-11-160","volume":"11","author":"Buhmann","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2018.04.002_b0235","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.13242","article-title":"Immunotherapy with the trifunctional anti-CD20\u202f\u00d7\u202fanti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies","volume":"169","author":"Schuster","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0240","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1080\/10428194.2016.1272687","article-title":"Immunotherapy with the trifunctional anti-CD20 \u00d7 anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease","volume":"58","author":"Kieslich","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2018.04.002_b0245","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbmt.2013.03.010","article-title":"CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma","volume":"19","author":"Lum","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2018.04.002_b0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/bmt.2013.133","article-title":"Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study","volume":"49","author":"Lum","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0255","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood.V128.22.621.621","article-title":"Phase 1 Study of REGN1979, an Anti-CD20\u202f\u00d7\u202fAnti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy","volume":"128","author":"Bannerji","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0260","doi-asserted-by":"crossref","unstructured":"Bannerji R, Advani RH, Brown JR, Arnason JE, Barnes JA, Allan JN, et al. Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20\u202f\u00d7\u202fAnti-CD3 bispecific antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy. Blood 2017;130(suppl.):1550.","DOI":"10.1182\/blood.V128.22.621.621"},{"key":"10.1016\/j.ctrv.2018.04.002_b0265","unstructured":"Topp MS, Borchmann P, Wagner-Johnston ND, Provencio M, Cordoba R, Papadopoulos K, et al. Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20\u202f\u00d7\u202fAnti-CD3 bispecific antibody, in Patients with B-Lymphoid Malignancies. Blood 2017, 130 (suppl.):1495."},{"key":"10.1016\/j.ctrv.2018.04.002_b0270","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific anitbodies for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0275","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood.V128.22.1836.1836","article-title":"CD20 Tcb (RG6026), a Novel \u201c2:1\u201d T Cell bispecific antibody for the Treatment of B Cell Malignancies","volume":"129","author":"Bacac","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0280","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.26420\/annhematoloncol.2017.1174","article-title":"Blinatumomab Induced Response of Multiply Refractory Multiple Myeloma in the Context of Secondary Pre-B Cell ALL","volume":"4","author":"Pratz","year":"2017","journal-title":"Ann Hematol Oncol"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0285","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.V130.Suppl_1.740.740","article-title":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a multicenter study of bb2121 Anti-Bcma CAR T cell therapy","volume":"130","author":"Berdeja","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0290","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2018.04.002_b0295","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0300","first-page":"500","article-title":"Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3\/CD38 antibody","volume":"129","author":"De Zafra","year":"2017","journal-title":"Blood"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0305","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/blood.V124.21.4727.4727","article-title":"Immunotherapy with long-lived Anti-CD38 \u00d7 anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in monkeys: a potential therapy for multiple myeloma","volume":"124","author":"Chu","year":"2014","journal-title":"Blood"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0310","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1182\/blood.V126.23.1798.1798","article-title":"Tuning T cell affinity improves efficacy and safety of anti-CD38 \u00d7 anti-CD3 bispecific antibodies in Monkeys - a potential therapy for multiple myeloma","volume":"126","author":"Moore","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0315","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1038\/bcj.2017.2","article-title":"Acute myeloid leukemia targets for bispecific antibodies","volume":"7","author":"Hoseini","year":"2017","journal-title":"Blood Cancer J"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0320","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.V130.Suppl_1.637.637","article-title":"Preliminary results of a phase 1 study of flotetuzumab, a CD123\u202f\u00d7\u202fCD3 bispecific Dart\u00ae Protein, in patients with relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"30","author":"Uy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0325","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2018.04.002_b0330","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2001-12-0295","article-title":"Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma","volume":"100","author":"Borchmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0335","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0340","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to haematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0345","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibodies targets T-cell cytotoxicity in cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"Nov EMBO Mol Med"},{"key":"10.1016\/j.ctrv.2018.04.002_b0350","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.002_b0355","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2018.04.002_b0360","doi-asserted-by":"crossref","first-page":"27130","DOI":"10.1038\/srep27130","article-title":"T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies","volume":"6","author":"Velasquez","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2018.04.002_b0365","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1038\/bcj.2015.73","article-title":"Bispecific antibodies releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts","volume":"5","author":"Aliperta","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2018.04.002_b0370","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-017-0397-z","article-title":"Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3\/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan","volume":"10","author":"Zhang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2018.04.002_b0375","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/hum.2016.122","article-title":"Treatment of human B-cell lymphomas using minicircle DNA vector expressing anti-CD3\/CD20 in a mouse model","volume":"28","author":"Pang","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ctrv.2018.04.002_b0380","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/protein\/gzx043","article-title":"Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells","volume":"30","author":"Gantke","year":"2017","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.ctrv.2018.04.002_b0385","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/0008-5472.CAN-14-1670","article-title":"Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER\/MET crosstalk","volume":"75","author":"Hu","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.04.002_b0390","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.04.002_b0395","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0400","first-page":"581","article-title":"High durable CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort","volume":"130","author":"Abramson","year":"2017","journal-title":"Blood"},{"issue":"supplement","key":"10.1016\/j.ctrv.2018.04.002_b0405","first-page":"577","article-title":"Primary analysis of Juliet: a global, pivotal, phase 2 Trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"130","author":"Schuster","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2018.04.002_b0410","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"37","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218300355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T22:02:19Z","timestamp":1660773739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737218300355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":82,"alternative-id":["S0305737218300355"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibodies in haematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}